AR015557A1 - Compuestos de 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas y composicion farmaceutica - Google Patents
Compuestos de 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas y composicion farmaceuticaInfo
- Publication number
- AR015557A1 AR015557A1 ARP990103992A ARP990103992A AR015557A1 AR 015557 A1 AR015557 A1 AR 015557A1 AR P990103992 A ARP990103992 A AR P990103992A AR P990103992 A ARP990103992 A AR P990103992A AR 015557 A1 AR015557 A1 AR 015557A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aminosulfonyl
- carboxy
- hydroxy
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 2
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010003645 Atopy Diseases 0.000 abstract 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 206010044248 Toxic shock syndrome Diseases 0.000 abstract 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000002917 arthritic effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000006583 body weight regulation Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- -1 cyan or Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de la formula (I) o la sal farmacéuticamente aceptable del mismo; en la quecada uno de R1 y R2 se selecciona, independientemente, entre elgrupo compuesto por hidrogeno, alquilo C1-6, cicloalquilo C3-7, arilo C6-10, heteroarilo C5-9 yhet erocicloalquilo C2-9, donde los grupos alquilo,cicloalquilo, arilo, heteroarilo o heterocicloalquilo están opcionalmente sustituidos con halo, hidroxi, alquilo C1-6, alcoxi C1-6, amino, alquilamino C1-6,(alquil C1-6)2-amino, tio, alquiltio C1-6,cian o, carboxi, carboxi-alquilo C1-6, hidroxi-alquilo C1-6, acilo C1-6, aminosulfonilo, alquilaminosulfonilo C1-6 o(alquil C1-6)2-aminosulfonilo; y R3 es hidrogeno, halo, hidroxi, alquilo C1-6, alcoxi C1-6, amino, alquilamino C1-6, (alquilC1-6)2-amino, tio, alquiltio C1-6,carboxi, carboxi-alquilo C1-6, hidroxi-alquilo C1-6, acilo C1-6, aminosulfonilo, alquilaminosulfonilo C1-6 o (alquil C1-6)2-aminosulfonilo, util en eltratamiento de trastornos respiratorios, alérgicos, reumatoides,de regulacion d el peso corporal, inflamatorios y del sistema nervioso central, tales comoasma, enfermedad pulmonar obstructiva cronica, síndrome de enfermedades respiratorias en adultos, choque toxico, fibrosis, hipersensibilidad pulmonar,rinitisalérgica, dermatit is atopica, psoriasis, control de peso, artritis reumatoide, caquexia, enfermedad de Crohn, colitis ulcerosa, afecciones artríticas y otrasenfermedades inflamatorias, depresion, demencia multiinfarto y SIDA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9617698P | 1998-08-11 | 1998-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015557A1 true AR015557A1 (es) | 2001-05-02 |
Family
ID=22256080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103992A AR015557A1 (es) | 1998-08-11 | 1999-08-10 | Compuestos de 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas y composicion farmaceutica |
Country Status (44)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815951B2 (en) | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
| JP2004532809A (ja) * | 2000-11-02 | 2004-10-28 | リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク | ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法 |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| JP4494020B2 (ja) | 2002-03-15 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｉｖインテグラーゼ阻害剤として有用なｎ−（置換ベンジル）−８−ヒドロキシ−１，６−ナフチリジン−７−カルボキサミド |
| KR100454750B1 (ko) * | 2002-06-20 | 2004-11-03 | 삼성에스디아이 주식회사 | 유기 전계 발광 소자용 청색 발광 화합물 및 이를 사용한유기 전계 발광 소자 |
| HRP20050572A2 (en) * | 2002-11-27 | 2006-08-31 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| US6861422B2 (en) * | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| DE10349497A1 (de) * | 2003-10-23 | 2005-05-25 | Bayer Cropscience Ag | N-substituierte Pyrazolylcarboxanilide |
| DE102004002557A1 (de) * | 2004-01-17 | 2005-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen |
| JP2007517828A (ja) * | 2004-01-17 | 2007-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 気道の疾患を治療するための置換プテリジンの使用 |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060035903A1 (en) * | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US7759485B2 (en) * | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US20060074088A1 (en) * | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7728134B2 (en) * | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| EP1630163A1 (de) * | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004058337A1 (de) * | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
| WO2007014838A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| WO2009019205A1 (en) * | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| AU2013301870B2 (en) * | 2012-08-08 | 2017-04-27 | Merck Patent Gmbh | (Aza-)isoquinolinone derivatives |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US20150031699A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU165405B (es) * | 1972-06-29 | 1974-08-28 | ||
| US3856800A (en) * | 1973-02-26 | 1974-12-24 | Sterling Drug Inc | Process of preparing 1,4-dihydro-4-oxo-7-q-3-unsubstituted-1,8-naphthyridines from cyclic alkylidenyl n-(6-q-2-pyridyl) aminomethylenemalonates |
| US3882132A (en) * | 1973-03-08 | 1975-05-06 | Sterling Drug Inc | Preparation of 1-alkyl-1,4-dihydro-7-substituted-4-oxo-1,8-naphthyridine-3-carboxylic acids via the 3-aminomethyl analogs |
| EP0779292A4 (en) * | 1994-08-29 | 1997-09-24 | Yamanouchi Pharma Co Ltd | NEW NAPHTHYRIDE DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEM |
| JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
-
1999
- 1999-08-05 EP EP99933078A patent/EP1104420B1/en not_active Expired - Lifetime
- 1999-08-05 EE EEP200100085A patent/EE200100085A/xx unknown
- 1999-08-05 AP APAP/P/2001/002068A patent/AP2001002068A0/en unknown
- 1999-08-05 DK DK99933078T patent/DK1104420T3/da active
- 1999-08-05 NZ NZ509297A patent/NZ509297A/en not_active Application Discontinuation
- 1999-08-05 OA OA1200100032A patent/OA11591A/en unknown
- 1999-08-05 PL PL99346005A patent/PL346005A1/xx not_active Application Discontinuation
- 1999-08-05 HK HK02100400.2A patent/HK1038917A1/zh unknown
- 1999-08-05 BR BR9912902-7A patent/BR9912902A/pt not_active Application Discontinuation
- 1999-08-05 GE GEAP19995743A patent/GEP20033029B/en unknown
- 1999-08-05 CN CN99809505A patent/CN1312810A/zh active Pending
- 1999-08-05 DE DE69904602T patent/DE69904602T2/de not_active Expired - Fee Related
- 1999-08-05 PT PT99933078T patent/PT1104420E/pt unknown
- 1999-08-05 ES ES99933078T patent/ES2188194T3/es not_active Expired - Lifetime
- 1999-08-05 AU AU49249/99A patent/AU4924999A/en not_active Abandoned
- 1999-08-05 KR KR1020017001718A patent/KR20010072368A/ko not_active Ceased
- 1999-08-05 HR HR20010107A patent/HRP20010107A2/hr not_active Application Discontinuation
- 1999-08-05 CA CA002340180A patent/CA2340180A1/en not_active Abandoned
- 1999-08-05 HU HU0103466A patent/HUP0103466A3/hu unknown
- 1999-08-05 CZ CZ2001485A patent/CZ2001485A3/cs unknown
- 1999-08-05 AT AT99933078T patent/ATE229955T1/de not_active IP Right Cessation
- 1999-08-05 SK SK182-2001A patent/SK1822001A3/sk unknown
- 1999-08-05 TR TR2001/00433T patent/TR200100433T2/xx unknown
- 1999-08-05 WO PCT/IB1999/001390 patent/WO2000009504A1/en not_active Ceased
- 1999-08-05 ID IDW20010315A patent/ID27843A/id unknown
- 1999-08-05 JP JP2000564956A patent/JP2002522541A/ja active Pending
- 1999-08-05 IL IL14086899A patent/IL140868A0/xx unknown
- 1999-08-05 EA EA200100124A patent/EA200100124A1/ru unknown
- 1999-08-06 TW TW088113482A patent/TW542835B/zh active
- 1999-08-09 HN HN1999000130A patent/HN1999000130A/es unknown
- 1999-08-09 GT GT199900128A patent/GT199900128A/es unknown
- 1999-08-09 PE PE1999000802A patent/PE20000950A1/es not_active Application Discontinuation
- 1999-08-10 TN TNTNSN99155A patent/TNSN99155A1/fr unknown
- 1999-08-10 SV SV1999000120A patent/SV1999000120A/es not_active Application Discontinuation
- 1999-08-10 PA PA19998480001A patent/PA8480001A1/es unknown
- 1999-08-10 MA MA25723A patent/MA26669A1/fr unknown
- 1999-08-10 AR ARP990103992A patent/AR015557A1/es not_active Application Discontinuation
- 1999-08-10 DZ DZ990166A patent/DZ2866A1/xx active
- 1999-08-11 US US09/372,735 patent/US6174895B1/en not_active Expired - Fee Related
- 1999-08-11 CO CO99051075A patent/CO5130004A1/es unknown
-
2001
- 2001-01-16 IS IS5815A patent/IS5815A/is unknown
- 2001-02-07 ZA ZA200101040A patent/ZA200101040B/en unknown
- 2001-02-09 NO NO20010684A patent/NO20010684L/no not_active Application Discontinuation
- 2001-03-09 BG BG105321A patent/BG105321A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015557A1 (es) | Compuestos de 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas y composicion farmaceutica | |
| PA8449601A1 (es) | Derivados de nicotinamida | |
| DD202720A5 (de) | Verfahren zur herstellung von cephalosporinderivaten | |
| ES2574840T3 (es) | Derivados de amidas heterocíclicas como antagonistas de receptores p2x7 | |
| AR048023A1 (es) | Cetoamidas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| AU2017228870A1 (en) | Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections | |
| PT2046802E (pt) | Derivados de penamo 2-substituídos com metilo | |
| SU753361A3 (ru) | Способ получени ненасыщенных производных 7-ациламидо-3-цефем4-карбоновой кислоты или их солей | |
| EP1221446A1 (en) | Antibacterial cephalosporins | |
| US4692443A (en) | 3-bicyclicpyridinium-methyl cephalosporins | |
| FI891200A0 (fi) | Menetelmä terapeuttisesti käyttökelpoisten 5-substituoitujen /4,5-c/imidatsopyridiinijohdannaisten valmistamiseksi | |
| US4748172A (en) | 3-bicyclicpyridinium-methyl cephalosporins | |
| EP0135142B1 (de) | Cephalosporinderivate und Verfahren zu ihrer Herstellung | |
| JPH0899978A (ja) | セファロスポリン誘導体 | |
| ECSP993095A (es) | 1-aril-3- arilmetil -8 -naftiridin -4 (1h)-(onas) | |
| JPH0625254A (ja) | ２，２−二置換セフェムスルホン | |
| EP0035161B1 (de) | Cephalosporine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| JPH09506112A (ja) | セファロスポリン化合物およびその製造方法 | |
| KR100377559B1 (ko) | 경구투여 가능한 세팔로스포린계 화합물 및 이의 제조방법 | |
| EP1590354A2 (en) | Carboxylic acid esters of pharmaceutical compounds | |
| KR910008375B1 (ko) | 신규 세팔로스포린계 항생제 및 이의 제조방법 | |
| US4666835A (en) | 2-vinylpenams and process | |
| KR920002868B1 (ko) | 신규한 세팔로스포린 화합물과 그의 제조방법 | |
| EP1474428A1 (en) | Crystalline hydrochloride of 7- [(5-amino-1,2,4-thiadiazol-3-yl)(fluoromethoxyimino)acetyl]amino -3-[(imino-1-piperazinylmethyl)methylhydrazono]-methyl-3-cephem-4-carboxylic acid | |
| KR910007980B1 (ko) | 신규 세팔로스포린계 항생제 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |